A Phase 3 Registration Trial of ANG-3777 for Prevention of Cardiac-Surgery Associated Acute Kidney Injury (CSA-AKI)
Latest Information Update: 21 Jun 2023
At a glance
- Drugs Terevalefim (Primary)
- Indications Acute kidney injury
- Focus Registrational; Therapeutic Use
- Sponsors Angion Biomedica; Elicio Therapeutics
- 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
- 30 Apr 2021 New trial record
- 29 Apr 2021 According to an Angion Biomedica media release, the Phase 2 prevention trial (NCT02771509) was designed to generate data on ANG-3777 in CSA-AKI patients to help guide future development of ANG-3777 in this Phase 3 registration trial for CSA-AKI. The company is planning to start the confirmatory trial early in 2022, subject to the results of the Phase 2 trial (NCT02771509) as well as discussions with the FDA and other relevant health authorities.